Aaron's
NYSE:AANHeadquartered in Atlanta, The Aaron's Company, Inc. (NYSE: AAN) is a leading, technology-enabled, omnichannel provider of lease-purchase solutions. Aaron's engages in direct-to-consumer sales and lease ownership of furniture, appliances, consumer electronics and accessories through its approximately 1,300 company-operated and franchised stores in 47 states and Canada, as well as its e-commerce platform, Aarons.com. For more information, visit Aarons.com or investor.aarons.com.
Canasil Resources
CVE:CLZCanasil Resources Inc. engages in the exploration and development of mineral properties. The company explores for silver, gold, copper, zinc, and lead deposits. It holds 100% interests in the Salamandra zinc-silver project, the La Esperanza silver-gold-zinc-lead project, the Carina silver project, the Colibri silver-zinc-lead-copper project, the Vizcaino silver-gold project, and the Nora silver-gold-copper project located in Durango and Zacatecas States, Mexico. The company also has 100% interests in the Brenda gold-copper property, the Vega gold-copper property, the Granite gold property, and the LIL silver property situated in British Columbia, Canada. Canasil Resources Inc. was incorporated in 1984 and is headquartered in Vancouver, Canada.
Graphite One
CVE:GPHGraphite One Inc. operates as mineral exploration company in the United States. It holds interest in the Graphite Creek property that consists of 176 mining claims covering an area of 9,600 hectares located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Kodiak Sciences
NASDAQ:KODKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Norvista Capital
CVE:NVVNorvista Capital Corporation operates as a resource investment company and merchant bank in the United States and Canada. It invests in a portfolio of companies that are involved in the exploration of base and precious metals, such as copper, zinc, silver, gold, and lead, as well as oil and gas located in Chile, Manitoba, Yukon, Mexico, and Nevada; and oil and gas in Israel, the United States, Brazil, and Canada. The company was founded in 2014 and is headquartered in Toronto, Canada.